Cargando…
On the coherence of model-based dose-finding designs for drug combination trials
The concept of coherence was proposed for single-agent phase I clinical trials to describe the property that a design never escalates the dose when the most recently treated patient has toxicity and never de-escalates the dose when the most recently treated patient has no toxicity. It provides a use...
Autores principales: | Park, Yeonhee, Liu, Suyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703981/ https://www.ncbi.nlm.nih.gov/pubmed/33253260 http://dx.doi.org/10.1371/journal.pone.0242561 |
Ejemplares similares
-
Embracing model-based designs for dose-finding trials
por: Love, Sharon B, et al.
Publicado: (2017) -
Interval design to identify the optimal biological dose for immunotherapy
por: Park, Yeonhee
Publicado: (2022) -
A clinical phase I dose-finding design with adaptive shrinking boundaries for drug combination trials
por: Li, Zhaohang, et al.
Publicado: (2023) -
Modern dose-finding designs for cancer phase I trials: drug combinations and molecularly targeted agents
por: Hirakawa, Akihiro, et al.
Publicado: (2018) -
Personalized Risk-Based Screening Design for Comparative Two-Arm Group Sequential Clinical Trials
por: Park, Yeonhee
Publicado: (2022)